arrow
C

Christopher R. Flowers

university of texas
H指数:84
被引数:3.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluation of gene expression assays to classify large B-cell lymphoma by molecular subtype using formalin-fixed paraffin-embedded tumor biopsies

使用石蜡包埋肿瘤活检样本评估基因表达检测方法对大B细胞淋巴瘤进行分子亚型分类

2026-10-190
OAAI
Temporal trends in relative survival and excess mortality among US adults with lymphoid malignancies

美国淋巴恶性肿瘤患者相对生存率和超额死亡率的时序趋势

2026-09-240
PRE
Clinical utility of real-time comprehensive molecular testing in large B-cell lymphoma

实时全面分子检测在大型B细胞淋巴瘤中的临床应用

2026-07-290
OA
Treatment patterns and outcomes for second-line therapy in large B-cell lymphoma: results from the LEO CReWE study

大B细胞淋巴瘤二线治疗的治疗模式与疗效:LEO CReWE研究的结果

2026-07-230
OA
Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma

SMART START试验的长期临床结果:利妥昔单抗、来那度胺和伊布替尼在 newly diagnosed large B-cell lymphoma 患者中的应用

2026-07-020
OAAI
Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy

滤泡性淋巴瘤接受免疫化疗的治疗诊断至治疗间隔与结局相关

Blood
IF23.1
2026-04-160
PRE
Assessing patient perspectives on enrollment in lymphoma clinical trials

评估患者对淋巴瘤临床试验入组的看法

Cancer
IF5.1
2026-04-160
OAAI
Occurrence and predictors of patient reported fertility discussions in non-Hodgkin lymphoma patients: utilizing the lymphoma epidemiology of outcomes (LEO) cohort study
2025-11-010
PRE
Multi-modal spatial characterization of tumor immune microenvironments identifies targetable inflammatory niches in diffuse large B cell lymphoma

多模态空间表征肿瘤免疫微环境,识别弥漫性大B细胞淋巴瘤中可靶向的炎症微环境

2025-10-210
OAAI
Adaptation and Performance of the Self-Report-Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort

自评生成的Charlson合并症指数在淋巴瘤结局流行病学(LEO)队列中的适应性和表现

2025-10-070
PRE
PROs versus clinician-reported adverse events in a large clinical trial: findings from the Phase 3 POLARIX study

患者报告结果(PROs)与临床医生报告的不良事件在大型临床试验中的比较:来自III期POLARIX研究的结果

Blood
IF23.1
2025-09-290
OA
Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies

多中心研究:ALK阳性大B细胞淋巴瘤:ALK抑制剂和生物学指导治疗时代的结局

2025-09-030
PRE
Clinical Outcomes and Patterns of Care Among Patients with Newly Diagnosed Classical Hodgkin Lymphoma in a Safety-Net Health System

新诊断经典霍奇金淋巴瘤患者在安全网卫生系统中的临床结局与治疗模式

2025-08-140
PRE
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts

滤泡性淋巴瘤3B亚型具有不同的预后结局:来自前瞻性多中心MER和LEO队列的研究结果

2025-08-080
OAAI
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial

一线阿卡巴鲁替尼、来那度胺和利妥昔单抗治疗高肿瘤负荷的晚期滤泡性淋巴瘤:II期试验

2025-08-070
OAAI
Large B cell lymphoma microenvironment archetype profiles

大B细胞淋巴瘤微环境原型图谱

2025-06-180
OA
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma

一项奥滨尤妥珠单抗联合来那度胺治疗既往未治的高肿瘤负荷滤泡性淋巴瘤的II期研究

2025-06-170
OAAI